To evaluate the effect of maternal body mass index (BMI) on the administration of postpartum analgesic medications, especially the use of opioids. For many women, postpartum period represents the first exposure to opioids. Therefore, it is important to better elucidate the factors influencing the use of these medications. STUDY DESIGN: Retrospective cohort study of singleton deliveries at ! 37 weeks of gestation at a tertiary university hospital from 2013 -2016. Patients were excluded for the following: illicit drug use, positive urine toxicology, NSAID or opioid allergies, current smokers, and incomplete records. All standard analgesic medications administered during postpartum hospitalization were reviewed, including the dose and route of administration. Chi-square, Fisher's exact test and analysis of variance (ANOVA) were used where appropriate. Multivariate linear regression models were used to identify factors associated with the use of oxycodone in the postpartum period. RESULTS: A total of 16,085 pregnancies were included: 5,565 cesarean delivery (CD) and 10,520 vaginal delivery (VD). Women in each mode of delivery (MOD) group were stratified by standard BMI classifications. Baseline characteristics differed between the BMI classes in each MOD group, including neonatal birthweight and gestational weight gain. The amount of oxycodone consumed per day significantly increased in both MOD groups as BMI increased. Hydromorphone use did not increase with the increase in BMI in either MOD group. Morphine administration increased with BMI class in the VD group. Increased BMI was associated with increased use of oral acetaminophen and ibuprofen in both MOD groups. Multivariate linear regression showed that BMI ! 30kg/m 2 was independently associated with increased amounts of oxycodone consumption. Other factors that increased the use of medication were excessive weight gain during pregnancy, birthweight, total number of postpartum days, regional anesthesia and mode of delivery. The factors that decreased the consumption included advanced maternal age and higher gestational age at delivery. CONCLUSION: Maternal obesity (BMI ! 30 kg/m 2 ) is associated with increased consumption of inpatient postpartum pain medication, including opioid medications such as oxycodone and morphine.
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To evaluate the effect of maternal body mass index (BMI) on the administration of postpartum analgesic medications, especially the use of opioids. For many women, postpartum period represents the first exposure to opioids. Therefore, it is important to better elucidate the factors influencing the use of these medications. STUDY DESIGN: Retrospective cohort study of singleton deliveries at ! 37 weeks of gestation at a tertiary university hospital from 2013 -2016. Patients were excluded for the following: illicit drug use, positive urine toxicology, NSAID or opioid allergies, current smokers, and incomplete records. All standard analgesic medications administered during postpartum hospitalization were reviewed, including the dose and route of administration. Chi-square, Fisher's exact test and analysis of variance (ANOVA) were used where appropriate. Multivariate linear regression models were used to identify factors associated with the use of oxycodone in the postpartum period. RESULTS: A total of 16,085 pregnancies were included: 5,565 cesarean delivery (CD) and 10,520 vaginal delivery (VD). Women in each mode of delivery (MOD) group were stratified by standard BMI classifications. Baseline characteristics differed between the BMI classes in each MOD group, including neonatal birthweight and gestational weight gain. The amount of oxycodone consumed per day significantly increased in both MOD groups as BMI increased. Hydromorphone use did not increase with the increase in BMI in either MOD group. Morphine administration increased with BMI class in the VD group. Increased BMI was associated with increased use of oral acetaminophen and ibuprofen in both MOD groups. Multivariate linear regression showed that BMI ! 30kg/m 2 was independently associated with increased amounts of oxycodone consumption. Other factors that increased the use of medication were excessive weight gain during pregnancy, birthweight, total number of postpartum days, regional anesthesia and mode of delivery. The factors that decreased the consumption included advanced maternal age and higher gestational age at delivery. CONCLUSION: Maternal obesity (BMI ! 30 kg/m 2 ) is associated with increased consumption of inpatient postpartum pain medication, including opioid medications such as oxycodone and morphine. OBJECTIVE: There is no proven therapy to reverse or ameliorate fetal growth restriction (FGR). Phosphodiesterase5 inhibitor (PDE5) inhibitor is widely expected as therapeutic agent for FGR. We have designed this phase II trial to prospectively evaluating the effect of tadalafil, long acting PDE5 inhibitor, on the clinical therapy of women with FGR. STUDY DESIGN: This study was a multicenter randomized controlled phase II trial. 40 major medical center in Japan participated in this trial. Total number of cases we planned were 140. Cases were randomized into receive either the conventional FGR management according to the Japan guideline of obstetrics or the treatment with tadalafil (20mg/day) until delivery. Fetal growth velocity (g/day) from the first day of the treatment to birth has been defined as the primary endpoint, and secondary outcome included prolongation of GA at birth, defined as days from the first day of the protocoldefined treatment to birth, GA at birth, birth weight, and fetal growth rate. This study was approved by the Institutional Review Board of Mie University Hospital. RESULTS: Now we finished this trial on the way in March 2018. The Japan Agency for Medical Research and Development (AMED) recommended stop of our trial because STRIDER (Sildenafil Therapy in dismal prognosis early onset fetal growth restriction) UK group reported the negative data of administrating sildenafil for FGR as PDE5 inhibitor. 89 cases have registered in this trial. The fetal growth velocity between tadalafil treatment group and conventional treatment group was so far no significant (tadalafil treatment group 13.3(10.0-19.4) g/day vs conventional treatment 11.9(6.6-18.6) g/day p¼0.43). No difference was found in the prolongation of GA between conventional treatment group and tadalafil treatment group in all cases (35.5AE24.3day vs 46.0AE27.3day, p¼0.06). Notably, limiting to cases which were administered at less than 32 weeks or 30 weeks of GA, there were significant differences that tadalafil prolonged the pregnancy period compared with conventional treatment (below 32 weeks: 36.8AE26.8day vs 52.4AE28.9day, p¼0.03; below 30 weeks: 37.0AE30.5day vs 55.0AE30.4day, p¼0.04).
CONCLUSION:
Tadalafil has no effect for increasing the fetal growth velocity of FGR as primary outcome, however prolonged pregnancy period as secondary outcome. We will continuously follow up the long-term outcome of children. OBJECTIVE: A growing number of women with multiple gestations and a previous cesarean section (CS) are candidates for a trial of labor after cesarean (TOLAC). Evidence to guide decisions regarding optimal mode of delivery in this population is lacking. Our objective was to perform a systematic review and meta-analysis of success rates and maternal and neonatal outcomes in women with twin pregnancy attempting TOLAC versus elective repeat cesarean section (ERCS). STUDY DESIGN: We searched MEDLINE, Embase, and Web of Science from data inception to May 2018 with no language or regional restrictions, to identify all studies that compared TOLAC and ERCS in twin gestations for maternal and/or neonatal outcomes. Our primary outcome was adverse maternal and neonatal outcomes in either delivery mode. Newcastle-Ottawa Scale was used to assess the methodological quality of the included studies. We assessed the pooled relative risk and mean difference using a random-effects model of maternal and neonatal outcomes by comparing twin pregnancies with a previous CS that underwent TOLAC to ERCS. The pooled event rate for successful VBAC and uterine rupture in women who underwent TOLAC was determined using a random-effects model. RESULTS: Of the 841 citations identified, 10 were eligible for analysis (8,099 pregnancies, with 2,336 TOLAC cases and 5,763 ERCS cases, reporting the outcome of 3,188 neonates). The pooled event rate for a successful VBAC was 72.2% (95% CI 59.7-83.2%). The pooled event rate for uterine rupture during TOLAC was 0.87% (95% CI 0.51%-1.31%). TOLAC was associated with a significantly higher risk of neonatal death (RR 3.02: 95% CI, 1.07-8.54) compared to ERCS, with no significant differences in mean gestational age at delivery, NICU admission rates or 5' Apgar<7 between the groups. While infection rate was significantly lower in women undergoing TOLAC (RR 0.48: 95% CI, 0.25-0.90) the rate of, uterine rupture, hysterectomy and dehiscence was comparable. CONCLUSION: TOLAC in twins is associated with successful vaginal delivery of both twins in a majority of the cases with rupture rates of less than 1%. While maternal infectious morbidity decreases in TOLAC, the finding of increased rate of neonatal death raises concerns and requires further investigation. 
